Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1967 1
1968 6
1970 2
1972 2
1973 3
1974 3
1978 1
1979 2
1981 2
1982 1
1983 2
1988 1
1989 1
1990 1
1991 1
1992 1
1993 2
1994 4
1995 3
1996 2
1997 11
1998 6
1999 5
2000 9
2001 5
2002 11
2003 7
2004 11
2005 7
2006 21
2007 19
2008 20
2009 20
2010 24
2011 25
2012 20
2013 18
2014 26
2015 30
2016 33
2017 30
2018 23
2019 41
2020 59
2021 52
2022 30
2023 45
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

602 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. Among authors: coleman rl. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Matulonis UA, et al. Among authors: coleman rl. J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716407 Free PMC article. Clinical Trial.
Gestational choriocarcinoma.
Bogani G, Ray-Coquard I, Mutch D, Vergote I, Ramirez PT, Prat J, Concin N, Ngoi NYL, Coleman RL, Enomoto T, Takehara K, Denys H, Lorusso D, Takano M, Sagae S, Wimberger P, Segev Y, Kim SI, Kim JW, Herrera F, Mariani A, Brooks RA, Tan D, Paolini B, Chiappa V, Longo M, Raspagliesi F, Benedetti Panici P, Di Donato V, Caruso G, Colombo N, Pignata S, Zannoni G, Scambia G, Monk BJ. Bogani G, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2023 Oct 2;33(10):1504-1514. doi: 10.1136/ijgc-2023-004704. Int J Gynecol Cancer. 2023. PMID: 37758451 Review.
Biomarker-driven therapy in endometrial cancer.
Karpel H, Slomovitz B, Coleman RL, Pothuri B. Karpel H, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2023 Mar 6;33(3):343-350. doi: 10.1136/ijgc-2022-003676. Int J Gynecol Cancer. 2023. PMID: 36878569 Review.
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I; innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Coleman RL, et al. Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9. Lancet Oncol. 2021. PMID: 33845034 Clinical Trial.
Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC, Slomovitz B, Coleman RL, Pothuri B. Karpel HC, et al. Among authors: coleman rl. Curr Opin Obstet Gynecol. 2023 Jun 1;35(3):270-278. doi: 10.1097/GCO.0000000000000855. Epub 2023 Mar 20. Curr Opin Obstet Gynecol. 2023. PMID: 36943683 Review.
Exploring and comparing adverse events between PARP inhibitors.
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. LaFargue CJ, et al. Among authors: coleman rl. Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. Lancet Oncol. 2019. PMID: 30614472 Free PMC article. Review.
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS. Monk BJ, et al. Among authors: coleman rl. J Clin Oncol. 2022 Dec 1;40(34):3952-3964. doi: 10.1200/JCO.22.01003. Epub 2022 Jun 6. J Clin Oncol. 2022. PMID: 35658487 Free PMC article. Clinical Trial.
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.
Schmeler KM, Pareja R, Lopez Blanco A, Humberto Fregnani J, Lopes A, Perrotta M, Tsunoda AT, Cantú-de-León DF, Ramondetta LM, Manchana T, Crotzer DR, McNally OM, Riege M, Scambia G, Carvajal JM, Di Guilmi J, Rendon GJ, Ramalingam P, Fellman BM, Coleman RL, Frumovitz M, Ramirez PT. Schmeler KM, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2021 Oct;31(10):1317-1325. doi: 10.1136/ijgc-2021-002921. Epub 2021 Sep 7. Int J Gynecol Cancer. 2021. PMID: 34493587
602 results